TcLand Expression launches the "PRINT" international clinical trial to validate its blood biomarker RA-INF-Dx and announces the recruitment of its first patient

24-Feb-2011 - France

TcLand Expression SA announced the launch of the PRINT trial ("Predicting non-response to infliximab therapy") and the recruitment of its first patient in a French rheumatology center. PRINT is a prospective, international, multicenter trial seeking to validate the blood-based biomarker RA-INF-Dx as a predictive, multigene molecular diagnostic for identifying rheumatoid arthritis patients who are unlikely to respond to infliximab (Remicade®), a monoclonal antibody targeting tumor necrosis factor (TNF). In all, 200 patients will included in the study by around 25 investigating centers in 7 European countries.

"The RA-INF-Dx predictive blood test will constitute a major step forward in the management of rheumatoid arthritis patients. RA-INF-Dx will help to optimize treatment with infliximab by identifying non-responder patients prior to the initiation of anti-TNF therapy. This will enable clinicians to offer patients the most suitable treatment option, reduce the incidence of potential short- and long-term side effects and thus positively influence quality of care and overall healthcare costs", emphasized Patrick Larcier, Vice President of Clinical and Regulatory Affairs at TcLand Expression.

https://www.bionity.com/en/news/130989/tcland-expression-launches-the-print-international-clinical-trial-to-validate-its-blood-biomarker-ra-inf-dx-and-announces-the-recruitment-of-its-first-patient.html